PMLiVE5h
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Nasdaq3d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of ...
Daily1d
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
PharmiWeb3d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary ...
The Pharma Letter3d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Nasdaq3d
Gilead's Seladelpar Gets Conditional European Approval For Primary Biliary Cholangitis Treatment
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...